The Role of Adiponectin in Maintaining Metabolic Homeostasis

Author(s): Suleyman Cem Adiyaman*, Muhammet Ozer, Basak Ozgen Saydam, Baris Akinci.

Journal Name: Current Diabetes Reviews

Volume 16 , Issue 2 , 2020

Become EABM
Become Reviewer

Abstract:

Background: Adiponectin is an adipocyte-derived cytokine closely associated with obesity, altered body adipose tissue distribution, insulin resistance, and cardiovascular diseases.

Introduction: Evidence from animal and human studies demonstrate that adiponectin plays an important role in the regulation of glucose and lipid metabolism. Adiponectin increases insulin sensitivity and improves systemic lipid metabolism. Although research efforts on adiponectin mostly aim towards its endocrine functions, this adipocyte-derived molecule also has profound autocrine and paracrine functions.

Conclusion: In this review, our aim is to discuss the role of adiponectin in maintaining metabolic homeostasis and its association with cardiovascular health. The proper identification of these roles is of great importance, which has the potential to identify a wealth of novel targets for the treatment of diabetes and related cardio-metabolic diseases.

Keywords: Adiponectin, cardiovascular risk, diabetes, mortality, obesity, insulin resistance.

[1]
Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004; 145(5): 2273-82.
[http://dx.doi.org/10.1210/en.2003-1336] [PMID: 14726444]
[2]
Saddi-Rosa P, Oliveira CSV, Giuffrida FMA, Reis AF. Visfatin, glucose metabolism and vascular disease: A review of evidence. Diabetol Metab Syndr 2010; 2: 21.
[http://dx.doi.org/10.1186/1758-5996-2-21] [PMID: 20346149]
[3]
Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270(45): 26746-9.
[http://dx.doi.org/10.1074/jbc.270.45.26746] [PMID: 7592907]
[4]
Stern JH, Rutkowski JM, Scherer PE. Adiponectin, Leptin, and Fatty Acids in the Maintenance of Metabolic Homeostasis through Adipose Tissue Crosstalk. Cell Metab 2016; 23(5): 770-84.
[http://dx.doi.org/10.1016/j.cmet.2016.04.011] [PMID: 27166942]
[5]
Borges MC, Barros AJD, Ferreira DLS, et al. Metabolic profiling of adiponectin levels in adults: mendelian randomization analysis. Circ Cardiovasc Genet 2017; 10(6)e001837
[http://dx.doi.org/10.1161/CIRCGENETICS.117.001837] [PMID: 29237687]
[6]
Soininen P, Kangas AJ, Würtz P, et al. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst (Lond) 2009; 134(9): 1781-5.
[http://dx.doi.org/10.1039/b910205a] [PMID: 19684899]
[7]
Fasshauer M, Blüher M. Adipokines in health and disease. Trends Pharmacol Sci 2015; 36(7): 461-70.
[http://dx.doi.org/10.1016/j.tips.2015.04.014] [PMID: 26022934]
[8]
Li G, Xu L, Zhao Y, et al. Leptin-adiponectin imbalance as a marker of metabolic syndrome among Chinese children and adolescents: The BCAMS study. PLoS One 2017; 12(10)e0186222
[http://dx.doi.org/10.1371/journal.pone.0186222] [PMID: 29020116]
[9]
Cho E, Rimm EB, Stampfer MJ, Willett WC, Hu FB. The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. J Am Coll Cardiol 2002; 40(5): 954-60.
[http://dx.doi.org/10.1016/S0735-1097(02)02044-2] [PMID: 12225722]
[10]
Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339(4): 229-34.
[http://dx.doi.org/10.1056/NEJM199807233390404] [PMID: 9673301]
[11]
Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: More than just another fat cell hormone? Diabetes Care 2003; 26(8): 2442-50.
[http://dx.doi.org/10.2337/diacare.26.8.2442] [PMID: 12882876]
[12]
Takahashi M, Arita Y, Yamagata K, et al. Genomic structure and mutations in adipose-specific gene, adiponectin. International journal of obesity and related metabolic disorders. Journal of the International Association for the Study of Obesity 2000; 24(7): 861.
[http://dx.doi.org/10.1038/sj.ijo.0801244]
[13]
Kissebah AH, Sonnenberg GE, Myklebust J, et al. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci USA 2000; 97(26): 14478-83.
[http://dx.doi.org/10.1073/pnas.97.26.14478] [PMID: 11121050]
[14]
Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB. Adiponectin--A key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006; 8(3): 264-80.
[http://dx.doi.org/10.1111/j.1463-1326.2005.00510.x] [PMID: 16634986]
[15]
Qiang L, Wang H, Farmer SR. Adiponectin secretion is regulated by SIRT1 and the endoplasmic reticulum oxidoreductase Ero1-L alpha. Mol Cell Biol 2007; 27(13): 4698-707.
[http://dx.doi.org/10.1128/MCB.02279-06] [PMID: 17452443]
[16]
Wang ZV, Schraw TD, Kim JY, et al. Secretion of the adipocyte-specific secretory protein adiponectin critically depends on thiol-mediated protein retention. Mol Cell Biol 2007; 27(10): 3716-31.
[http://dx.doi.org/10.1128/MCB.00931-06] [PMID: 17353260]
[17]
Yamauchi T, Iwabu M, Okada-Iwabu M, Kadowaki T. Adiponectin receptors: A review of their structure, function and how they work. Best Pract Res Clin Endocrinol Metab 2014; 28(1): 15-23.
[http://dx.doi.org/10.1016/j.beem.2013.09.003] [PMID: 24417942]
[18]
Yamauchi T, Nio Y, Maki T, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007; 13(3): 332-9.
[http://dx.doi.org/10.1038/nm1557] [PMID: 17268472]
[19]
Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8(11): 1288-95.
[http://dx.doi.org/10.1038/nm788] [PMID: 12368907]
[20]
Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001; 108(12): 1875-81.
[http://dx.doi.org/10.1172/JCI14120] [PMID: 11748271]
[21]
Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001; 98(4): 2005-10.
[http://dx.doi.org/10.1073/pnas.98.4.2005] [PMID: 11172066]
[22]
Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7(8): 947-53.
[http://dx.doi.org/10.1038/90992] [PMID: 11479628]
[23]
Ceddia RB, Somwar R, Maida A, Fang X, Bikopoulos G, Sweeney G. Globular adiponectin increases GLUT4 translocation and glucose uptake but reduces glycogen synthesis in rat skeletal muscle cells. Diabetologia 2005; 48(1): 132-9.
[http://dx.doi.org/10.1007/s00125-004-1609-y] [PMID: 15619075]
[24]
Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116(7): 1784-92.
[http://dx.doi.org/10.1172/JCI29126] [PMID: 16823476]
[25]
Wang Y, Meng RW, Kunutsor SK, et al. Plasma adiponectin levels and type 2 diabetes risk: A nested case-control study in a Chinese population and an updated meta-analysis. Sci Rep 2018; 8(1): 406.
[http://dx.doi.org/10.1038/s41598-017-18709-9] [PMID: 29321603]
[26]
Cui XB, Wang C, Li L, et al. Insulin decreases myocardial adiponectin receptor 1 expression via PI3K/Akt and FoxO1 pathway. Cardiovasc Res 2012; 93(1): 69-78.
[http://dx.doi.org/10.1093/cvr/cvr273] [PMID: 22012952]
[27]
Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000; 102(11): 1296-301.
[http://dx.doi.org/10.1161/01.CIR.102.11.1296] [PMID: 10982546]
[28]
Yamauchi T, Kamon J, Waki H, et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003; 278(4): 2461-8.
[http://dx.doi.org/10.1074/jbc.M209033200] [PMID: 12431986]
[29]
Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423(6941): 762-9.
[http://dx.doi.org/10.1038/nature01705] [PMID: 12802337]
[30]
Bikman BT, Summers SA. Ceramides as modulators of cellular and whole-body metabolism. J Clin Invest 2011; 121(11): 4222-30.
[http://dx.doi.org/10.1172/JCI57144] [PMID: 22045572]
[31]
Chen Z, Peng IC, Sun W, et al. AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. Circ Res 2009; 104(4): 496-505.
[http://dx.doi.org/10.1161/CIRCRESAHA.108.187567] [PMID: 19131647]
[32]
Ouedraogo R, Wu X, Xu SQ, et al. Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: Evidence for involvement of a cAMP signaling pathway. Diabetes 2006; 55(6): 1840-6.
[http://dx.doi.org/10.2337/db05-1174] [PMID: 16731851]
[33]
Karastergiou K, Mohamed-Ali V. The autocrine and paracrine roles of adipokines. Mol Cell Endocrinol 2010; 318(1-2): 69-78.
[http://dx.doi.org/10.1016/j.mce.2009.11.011] [PMID: 19948207]
[34]
Carbone F, La Rocca C, Matarese G. Immunological functions of leptin and adiponectin. Biochimie 2012; 94(10): 2082-8.
[http://dx.doi.org/10.1016/j.biochi.2012.05.018] [PMID: 22750129]
[35]
Tsang JY, Li D, Ho D, et al. Novel immunomodulatory effects of adiponectin on dendritic cell functions. Int Immunopharmacol 2011; 11(5): 604-9.
[http://dx.doi.org/10.1016/j.intimp.2010.11.009] [PMID: 21094289]
[36]
Qi Y, Takahashi N, Hileman SM, et al. Adiponectin acts in the brain to decrease body weight. Nat Med 2004; 10(5): 524-9.
[http://dx.doi.org/10.1038/nm1029] [PMID: 15077108]
[37]
Kubota N, Yano W, Kubota T, et al. Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab 2007; 6(1): 55-68.
[http://dx.doi.org/10.1016/j.cmet.2007.06.003] [PMID: 17618856]
[38]
Okamoto M, Ohara-Imaizumi M, Kubota N, et al. Adiponectin induces insulin secretion in vitro and in vivo at a low glucose concentration. Diabetologia 2008; 51(5): 827-35.
[http://dx.doi.org/10.1007/s00125-008-0944-9] [PMID: 18369586]
[39]
Wijesekara N, Krishnamurthy M, Bhattacharjee A, Suhail A, Sweeney G, Wheeler MB. Adiponectin-induced ERK and Akt phosphorylation protects against pancreatic beta cell apoptosis and increases insulin gene expression and secretion. J Biol Chem 2010; 285(44): 33623-31.
[http://dx.doi.org/10.1074/jbc.M109.085084] [PMID: 20709750]
[40]
Lee YH, Magkos F, Mantzoros CS, Kang ES. Effects of leptin and adiponectin on pancreatic β-cell function. Metabolism 2011; 60(12): 1664-72.
[http://dx.doi.org/10.1016/j.metabol.2011.04.008] [PMID: 21632069]
[41]
Stefan N, Vozarova B, Funahashi T, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002; 51(6): 1884-8.
[http://dx.doi.org/10.2337/diabetes.51.6.1884] [PMID: 12031977]
[42]
Stefan N, Stumvoll M, Vozarova B, et al. Plasma adiponectin and endogenous glucose production in humans. Diabetes Care 2003; 26(12): 3315-9.
[http://dx.doi.org/10.2337/diacare.26.12.3315] [PMID: 14633820]
[43]
Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: Relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 2003; 52(7): 1779-85.
[http://dx.doi.org/10.2337/diabetes.52.7.1779] [PMID: 12829646]
[44]
Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20(6): 1595-9.
[http://dx.doi.org/10.1161/01.ATV.20.6.1595] [PMID: 10845877]
[45]
Krakoff J, Funahashi T, Stehouwer CD, et al. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 2003; 26(6): 1745-51.
[http://dx.doi.org/10.2337/diacare.26.6.1745] [PMID: 12766104]
[46]
Mente A, Meyre D, Lanktree MB, et al. Causal relationship between adiponectin and metabolic traits: A Mendelian randomization study in a multiethnic population. PLoS One 2013; 8(6)e66808
[http://dx.doi.org/10.1371/journal.pone.0066808] [PMID: 23826141]
[47]
Gao H, Fall T, van Dam RM, et al. Evidence of a causal relationship between adiponectin levels and insulin sensitivity: a Mendelian randomization study. Diabetes 2013; 62(4): 1338-44.
[http://dx.doi.org/10.2337/db12-0935] [PMID: 23274890]
[48]
Yaghootkar H, Lamina C, Scott RA, et al. Mendelian randomization studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetes. Diabetes 2013; 62(10): 3589-98.
[http://dx.doi.org/10.2337/db13-0128] [PMID: 23835345]
[49]
Lindström T, Frystyk J, Hedman CA, Flyvbjerg A, Arnqvist HJ. Elevated circulating adiponectin in type 1 diabetes is associated with long diabetes duration. Clin Endocrinol (Oxf) 2006; 65(6): 776-82.
[http://dx.doi.org/10.1111/j.1365-2265.2006.02666.x] [PMID: 17121530]
[50]
Duncan BB, Schmidt MI, Pankow JS, et al. Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2004; 53(9): 2473-8.
[http://dx.doi.org/10.2337/diabetes.53.9.2473] [PMID: 15331562]
[51]
Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002; 360(9326): 57-8.
[http://dx.doi.org/10.1016/S0140-6736(02)09335-2] [PMID: 12114044]
[52]
Yamamoto S, Matsushita Y, Nakagawa T, Hayashi T, Noda M, Mizoue T. Circulating adiponectin levels and risk of type 2 diabetes in the Japanese. Nutr Diabetes 2014; 4(8)e130
[http://dx.doi.org/10.1038/nutd.2014.27] [PMID: 25133442]
[53]
Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: A systematic review and meta-analysis. JAMA 2009; 302(2): 179-88.
[http://dx.doi.org/10.1001/jama.2009.976] [PMID: 19584347]
[54]
Mather KJ, Funahashi T, Matsuzawa Y, et al. Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes 2008; 57(4): 980-6.
[http://dx.doi.org/10.2337/db07-1419] [PMID: 18192541]
[55]
Mantzoros CS, Li T, Manson JE, Meigs JB, Hu FB. Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. J Clin Endocrinol Metab 2005; 90(8): 4542-8.
[http://dx.doi.org/10.1210/jc.2005-0372] [PMID: 15914524]
[56]
Williams MA, Qiu C, Muy-Rivera M, Vadachkoria S, Song T, Luthy DA. Plasma adiponectin concentrations in early pregnancy and subsequent risk of gestational diabetes mellitus. J Clin Endocrinol Metab 2004; 89(5): 2306-11.
[http://dx.doi.org/10.1210/jc.2003-031201] [PMID: 15126557]
[57]
Snijder MB, Heine RJ, Seidell JC, et al. Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: The hoorn study. Diabetes Care 2006; 29(11): 2498-503.
[http://dx.doi.org/10.2337/dc06-0952] [PMID: 17065691]
[58]
Wannamethee SG, Lowe GDO, Rumley A, Cherry L, Whincup PH, Sattar N. Adipokines and risk of type 2 diabetes in older men. Diabetes Care 2007; 30(5): 1200-5.
[http://dx.doi.org/10.2337/dc06-2416] [PMID: 17322479]
[59]
Spranger J, Kroke A, Möhlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361(9353): 226-8.
[http://dx.doi.org/10.1016/S0140-6736(03)12255-6] [PMID: 12547549]
[60]
Yamamoto Y, Hirose H, Saito I, et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond) 2002; 103(2): 137-42.
[http://dx.doi.org/10.1042/cs1030137] [PMID: 12149104]
[61]
Matsubara M, Maruoka S, Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol 2002; 147(2): 173-80.
[http://dx.doi.org/10.1530/eje.0.1470173] [PMID: 12153737]
[62]
Borges MC, Oliveira IO, Freitas DF, et al. Obesity-induced hypoadiponectinaemia: the opposite influences of central and peripheral fat compartments. Int J Epidemiol 2017; 46(6): 2044-55.
[http://dx.doi.org/10.1093/ije/dyx022] [PMID: 28369345]
[63]
Fain JN, Buehrer B, Tichansky DS, Madan AK. Regulation of adiponectin release and demonstration of adiponectin mRNA as well as release by the non-fat cells of human omental adipose tissue. Intern J Obesity 2005; 32(3): 429-35.
[http://dx.doi.org/10.1038/sj.ijo.0803745]
[64]
Kim JY, van de Wall E, Laplante M, et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 2007; 117(9): 2621-37.
[http://dx.doi.org/10.1172/JCI31021] [PMID: 17717599]
[65]
Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86(5): 1930-5.
[http://dx.doi.org/10.1210/jcem.86.5.7463] [PMID: 11344187]
[66]
Gar C, Rottenkolber M, Grallert H, et al. Physical fitness and plasma leptin in women with recent gestational diabetes. PLoS One 2017; 12(6)e0179128
[http://dx.doi.org/10.1371/journal.pone.0179128] [PMID: 28609470]
[67]
Erhardt E, Foraita R, Pigeot I, et al. Reference values for leptin and adiponectin in children below the age of 10 based on the IDEFICS cohort. Int J Obes 2014; 38(Suppl. 2): S32-8.
[http://dx.doi.org/10.1038/ijo.2014.133] [PMID: 25219410]
[68]
Polyzos SA, Kountouras J, Zavos C, Tsiaousi E. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab 2010; 12(5): 365-83.
[http://dx.doi.org/10.1111/j.1463-1326.2009.01176.x] [PMID: 20415685]
[69]
Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: A systematic review and meta-analysis. Metabolism 2011; 60(3): 313-26.
[http://dx.doi.org/10.1016/j.metabol.2010.09.003] [PMID: 21040935]
[70]
Polyzos SA, Mantzoros CS. Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review. Metabolism 2016; 65(9): 1297-306.
[http://dx.doi.org/10.1016/j.metabol.2016.05.013] [PMID: 27506737]
[71]
Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257(1): 79-83.
[http://dx.doi.org/10.1006/bbrc.1999.0255] [PMID: 10092513]
[72]
Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett 2006; 580(12): 2917-21.
[http://dx.doi.org/10.1016/j.febslet.2006.04.028] [PMID: 16674947]
[73]
Obata Y, Yamada Y, Kyo M, et al. Serum adiponectin levels predict the risk of coronary heart disease in Japanese patients with type 2 diabetes. J Diabetes Investig 2013; 4(5): 475-82.
[http://dx.doi.org/10.1111/jdi.12078] [PMID: 24843698]
[74]
Costacou T, Zgibor JC, Evans RW, et al. The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. Diabetologia 2005; 48(1): 41-8.
[http://dx.doi.org/10.1007/s00125-004-1597-y] [PMID: 15616802]
[75]
Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005; 54(2): 534-9.
[http://dx.doi.org/10.2337/diabetes.54.2.534] [PMID: 15677512]
[76]
Lim S, Koo BK, Cho SW, et al. Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: The Korean atherosclerosis study (KAS): a 42-month prospective study. Atherosclerosis 2008; 196(1): 398-404.
[http://dx.doi.org/10.1016/j.atherosclerosis.2006.11.017] [PMID: 17178123]
[77]
Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291(14): 1730-7.
[http://dx.doi.org/10.1001/jama.291.14.1730] [PMID: 15082700]
[78]
Wu ZJ, Cheng YJ, Gu WJ, Aung LH. Adiponectin is associated with increased mortality in patients with already established cardiovascular disease: A systematic review and meta-analysis. Metabolism 2014; 63(9): 1157-66.
[http://dx.doi.org/10.1016/j.metabol.2014.05.001] [PMID: 24933398]
[79]
Bertolami A, de Lima-Júnior JC, Cintra RM, et al. Adiponectin concentration data improve the estimation of atherosclerotic risk in normal and in overweight subjects. Clin Endocrinol (Oxf) 2018; 88(3): 388-96.
[http://dx.doi.org/10.1111/cen.13540] [PMID: 29280189]
[80]
Schöttker B, Herder C, Rothenbacher D, et al. Proinflammatory cytokines, adiponectin, and increased risk of primary cardiovascular events in diabetic patients with or without renal dysfunction: results from the ESTHER study. Diabetes Care 2013; 36(6): 1703-11.
[http://dx.doi.org/10.2337/dc12-1416] [PMID: 23378623]
[81]
Hou H, Ge S, Zhao L, et al. An updated systematic review and meta-analysis of association between adiponectin gene polymorphisms and coronary artery disease. OMICS 2017; 21(6): 340-51.
[http://dx.doi.org/10.1089/omi.2017.0007] [PMID: 28617663]
[82]
Richards JB, Waterworth D, O’Rahilly S, et al. A genome-wide association study reveals variants in ARL15 that influence adiponectin levels. PLoS Genet 2009; 5(12)e1000768
[http://dx.doi.org/10.1371/journal.pgen.1000768] [PMID: 20011104]
[83]
Liu G, Ding M, Chiuve SE, et al. Plasma levels of fatty acid-binding protein 4, retinol-binding protein 4, high-molecular-weight adiponectin, and cardiovascular mortality among men with type 2 diabetes: A 22-year prospective study. Arterioscler Thromb Vasc Biol 2016; 36(11): 2259-67.
[http://dx.doi.org/10.1161/ATVBAHA.116.308320] [PMID: 27609367]
[84]
Borges MC, Lawlor DA, de Oliveira C, White J, Horta BL, Barros AJ. Role of adiponectin in coronary heart disease risk: A mendelian randomization study. Circ Res 2016; 119(3): 491-9.
[http://dx.doi.org/10.1161/CIRCRESAHA.116.308716] [PMID: 27252388]
[85]
Turer AT, Scherer PE. Adiponectin: Just along for the ride? Circ Res 2016; 119(3): 407-8.
[http://dx.doi.org/10.1161/CIRCRESAHA.116.309226] [PMID: 27458194]
[86]
Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma protein adiponectin. Circulation 1999; 100(25): 2473-6.
[http://dx.doi.org/10.1161/01.CIR.100.25.2473] [PMID: 10604883]
[87]
Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003; 278(45): 45021-6.
[http://dx.doi.org/10.1074/jbc.M307878200] [PMID: 12944390]
[88]
Kobayashi H, Ouchi N, Kihara S, et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 2004; 94(4): e27-31.
[http://dx.doi.org/10.1161/01.RES.0000119921.86460.37] [PMID: 14752031]
[89]
Okamoto Y, Arita Y, Nishida M, et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 2000; 32(2): 47-50.
[http://dx.doi.org/10.1055/s-2007-978586] [PMID: 10741683]
[90]
Daimon M, Oizumi T, Saitoh T, et al. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: the Funagata study. Diabetes Care 2003; 26(7): 2015-20.
[http://dx.doi.org/10.2337/diacare.26.7.2015] [PMID: 12832305]
[91]
Yamaguchi N, Argueta JG, Masuhiro Y, et al. Adiponectin inhibits Toll-like receptor family-induced signaling. FEBS Lett 2005; 579(30): 6821-6.
[http://dx.doi.org/10.1016/j.febslet.2005.11.019] [PMID: 16325814]
[92]
Lovren F, Pan Y, Quan A, et al. Adiponectin primes human monocytes into alternative anti-inflammatory M2 macrophages. Am J Physiol Heart Circ Physiol 2010; 299(3): H656-63.
[http://dx.doi.org/10.1152/ajpheart.00115.2010] [PMID: 20622108]
[93]
Okamoto Y, Kihara S, Ouchi N, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002; 106(22): 2767-70.
[http://dx.doi.org/10.1161/01.CIR.0000042707.50032.19] [PMID: 12451000]
[94]
Zhu W, Cheng KK, Vanhoutte PM, Lam KS, Xu A. Vascular effects of adiponectin: Molecular mechanisms and potential therapeutic intervention. Clinical Science 2008; 114(5): 361-74.
[http://dx.doi.org/10.1042/CS20070347]
[95]
Wulster-Radcliffe MC, Ajuwon KM, Wang J, Christian JA, Spurlock ME. Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 2004; 316(3): 924-9.
[http://dx.doi.org/10.1016/j.bbrc.2004.02.130] [PMID: 15033490]
[96]
Kumada M, Kihara S, Ouchi N, et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004; 109(17): 2046-9.
[http://dx.doi.org/10.1161/01.CIR.0000127953.98131.ED] [PMID: 15096450]
[97]
Tan KC, Xu A, Chow WS, et al. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab 2004; 89(2): 765-9.
[http://dx.doi.org/10.1210/jc.2003-031012] [PMID: 14764794]
[98]
Pilz S, Horejsi R, Möller R, et al. Early atherosclerosis in obese juveniles is associated with low serum levels of adiponectin. J Clin Endocrinol Metab 2005; 90(8): 4792-6.
[http://dx.doi.org/10.1210/jc.2005-0167] [PMID: 15928248]
[99]
Nilsson PM, Engström G, Hedblad B, et al. Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance. Arterioscler Thromb Vasc Biol 2006; 26(12): 2758-62.
[http://dx.doi.org/10.1161/01.ATV.0000249638.01416.4b] [PMID: 17038635]
[100]
Kou H, Deng J, Gao D, et al. Relationship among adiponectin, insulin resistance and atherosclerosis in non-diabetic hypertensive patients and healthy adults. Clin Exp Hypertens 2018; 40(7): 656-63.
[http://dx.doi.org/10.1080/10641963.2018.1425414] [PMID: 29336612]
[101]
Wang M, Wang D, Zhang Y, Wang X, Liu Y, Xia M. Adiponectin increases macrophages cholesterol efflux and suppresses foam cell formation in patients with type 2 diabetes mellitus. Atherosclerosis 2013; 229(1): 62-70.
[http://dx.doi.org/10.1016/j.atherosclerosis.2013.01.017] [PMID: 23466101]
[102]
Tian L, Luo N, Klein RL, Chung BH, Garvey WT, Fu Y. Adiponectin reduces lipid accumulation in macrophage foam cells. Atherosclerosis 2009; 202(1): 152-61.
[http://dx.doi.org/10.1016/j.atherosclerosis.2008.04.011] [PMID: 18511057]
[103]
Chen M-C, Lee C-J, Yang C-F, Chen Y-C, Wang J-H, Hsu B-G. Low serum adiponectin level is associated with metabolic syndrome and is an independent marker of peripheral arterial stiffness in hypertensive patients. Diabetol Metab Syndr 2017; 9: 49.
[http://dx.doi.org/10.1186/s13098-017-0247-8] [PMID: 28670347]
[104]
Menzaghi C, Trischitta V. The adiponectin paradox for all-cause and cardiovascular mortality. Diabetes 2018; 67(1): 12-22.
[http://dx.doi.org/10.2337/dbi17-0016] [PMID: 29263167]
[105]
Choi SH, Ku EJ, Hong ES, et al. High serum adiponectin concentration and low body mass index are significantly associated with increased all-cause and cardiovascular mortality in an elderly cohort, “adiponectin paradox”: The Korean Longitudinal Study on Health and Aging (KLoSHA). Int J Cardiol 2015; 183: 91-7.
[http://dx.doi.org/10.1016/j.ijcard.2015.01.057] [PMID: 25662058]
[106]
Menon V, Li L, Wang X, et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 2006; 17(9): 2599-606.
[http://dx.doi.org/10.1681/ASN.2006040331] [PMID: 16885405]
[107]
Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005; 112(12): 1756-62.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.104.530972] [PMID: 16157772]
[108]
George J, Patal S, Wexler D, et al. Circulating adiponectin concentrations in patients with congestive heart failure. Heart 2006; 92(10): 1420-4.
[http://dx.doi.org/10.1136/hrt.2005.083345] [PMID: 16621874]
[109]
Forsblom C, Thomas MC, Moran J, et al. Serum adiponectin concentration is a positive predictor of all-cause and cardiovascular mortality in type 1 diabetes. J Intern Med 2011; 270(4): 346-55.
[http://dx.doi.org/10.1111/j.1365-2796.2011.02406.x] [PMID: 21615808]
[110]
Menzaghi C, Xu M, Salvemini L, et al. Circulating adiponectin and cardiovascular mortality in patients with type 2 diabetes mellitus: evidence of sexual dimorphism. Cardiovasc Diabetol 2014; 13: 130.
[http://dx.doi.org/10.1186/s12933-014-0130-y] [PMID: 25200659]
[111]
Dekker JM, Funahashi T, Nijpels G, et al. Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab 2008; 93(4): 1489-96.
[http://dx.doi.org/10.1210/jc.2007-1436] [PMID: 18211973]
[112]
Gardener H, Goldberg R, Mendez AJ, et al. Adiponectin and risk of vascular events in the Northern Manhattan study. Atherosclerosis 2013; 226(2): 483-9.
[http://dx.doi.org/10.1016/j.atherosclerosis.2012.11.020] [PMID: 23245751]
[113]
Witberg G, Ayers CR, Turer AT, et al. Relation of adiponectin to all-cause mortality, cardiovascular mortality, and major adverse cardiovascular events (from the dallas heart study). Am J Cardiol 2016; 117(4): 574-9.
[http://dx.doi.org/10.1016/j.amjcard.2015.11.067] [PMID: 26800774]
[114]
Hadjadj S, Aubert R, Fumeron F, et al. SURGENE study group; DESIR study group.. Increased plasma adiponectin concentrations are associated with microangiopathy in type 1 diabetic subjects. Diabetologia 2005; 48(6): 1088-92.
[http://dx.doi.org/10.1007/s00125-005-1747-x] [PMID: 15875155]
[115]
Bergmark BA, Cannon CP, White WB, et al. Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial. Diabetes Obes Metab 2017; 19(7): 962-9.
[http://dx.doi.org/10.1111/dom.12905] [PMID: 28195387]
[116]
Ortega Moreno L, Lamacchia O, Salvemini L, et al. The paradoxical association of adiponectin with mortality rate in patients with type 2 diabetes: Evidence of synergism with kidney function. Atherosclerosis 2016; 245: 222-7.
[http://dx.doi.org/10.1016/j.atherosclerosis.2015.12.026] [PMID: 26735588]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 2
Year: 2020
Page: [95 - 103]
Pages: 9
DOI: 10.2174/1573399815666190702155733
Price: $65

Article Metrics

PDF: 18

Special-new-year-discount